Horibe K, Katayama I, Miyajima Y, Matsumoto K, Fukuda M, Yoshida J, Kudo K, Kato K, Kojima S, Matsuyama T
Department of Pediatrics, Nagoya University School of Medicine.
Rinsho Ketsueki. 1994 Jul;35(7):657-64.
We reported the treatment outcome of Protocol 8704T, which included repeated L-asparaginase, for childhood T cell malignancies. Fifteen cases of acute lymphoblastic leukemia (T-ALL) and 11 cases of non-Hodgkin's lymphoma (T-NHL), aged 3 to 14 yrs (median 6 yrs), were enrolled. Twelve T-ALL had mediastinal mass. Murphy's stages of T-NHL were 6 with III and 5 with IV. Types of histology consisted of 8 lymphoblastic and 3 large cell. Treatment was performed for 2 years. Observation periods were from 14 months to 78 months (median 42 months). Twenty-three achieved remission and 6 of them were transplanted with bone marrow or peripheral stem cells in the first remission. The protocol was continued in 17 cases. Fourteen of them remain in first remission, but one died of measles and 2 died of relapse. The 5-year event-free survival was 76.1% for ALL and 65.5% for NHL. In terms of histology, it was 87.5% for lymphoblastic NHL and 33.3% for large cell NHL (p = 0.19). In terms of phenotypes in ALL, it was 88.7% for ALL positive to CD2, 5 and 7, while 2 ALL positive to CD7 alone both failed. Therefore, it was shown that this treatment protocol is very effective for T-lymphoblastic leukemia and lymphoma.
我们报告了8704T方案的治疗结果，该方案包括重复使用L-天冬酰胺酶，用于治疗儿童T细胞恶性肿瘤。纳入了15例急性淋巴细胞白血病（T-ALL）和11例非霍奇金淋巴瘤（T-NHL），年龄3至14岁（中位年龄6岁）。12例T-ALL有纵隔肿块。T-NHL的墨菲分期为Ⅲ期6例，Ⅳ期5例。组织学类型包括8例淋巴母细胞型和3例大细胞型。治疗进行了2年。观察期为14个月至78个月（中位42个月）。23例获得缓解，其中6例在首次缓解时接受了骨髓或外周干细胞移植。17例继续使用该方案。其中14例仍处于首次缓解期，但1例死于麻疹，2例死于复发。ALL的5年无事件生存率为76.1%，NHL为65.5%。就组织学而言，淋巴母细胞型NHL为87.5%，大细胞型NHL为33.3%（p = 0.19）。就ALL的表型而言，CD2、5和7阳性的ALL为88.7%，而仅CD7阳性的2例ALL均治疗失败。因此，表明该治疗方案对T淋巴细胞白血病和淋巴瘤非常有效。
